The landscape of treatment for bronchiectasis could change significantly with the approval of brensocatib, offering a more ...

The approval of brensocatib for use in patients with bronchiectasis could offer the first treatment directly addressing the ...

BRONCHIECTASIS is protean in its expressions as it is sometimes obscure in its origin. The clinical picture varies in individual patients, but common to the severer cases is a history of harassing ...

Long-term antibiotics use carries the risk of resistance and side effects, representing a gap in the market for a different ...

Bronchiectasis is a chronic airway suppurative disease in which recurrent airway infections, inflammation and remodeling have ...

Bronchiectasis impacts up to 500,000 Americans, but there is often misdiagnosis or delayed diagnosis as the condition can present similarly to other pulmonary conditions such as COPD or asthma.

Next-generation metagenomic sequencing has uncovered key differences in bronchiectasis pathogens and resistance genes across Europe.

Targeting airway inflammation with investigational brensocatib reduced exacerbations with bronchiectasis, the ASPEN trial showed. The dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized ...

Dublin, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The "Bronchiectasis - Market Insight, Epidemiology and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report ...

Please provide your email address to receive an email when new articles are posted on . Having a chronic respiratory infection in addition to bronchiectasis heightened the risk for an exacerbation ...

A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

British scientists have found the first-ever treatment for bronchiectasis, the disease Pope Francis was hospitalized with in the weeks prior to his death, The Telegraph reported. Francis suffered ...